Prøve GULL - Gratis

The Strategic Rise of India's Deep-Science Economy

BioSpectrum Asia

|

BioSpectrum Asia Feb 2026

India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.

The Strategic Rise of India's Deep-Science Economy

With initiatives such as the $12 billion Research, Development and Innovation (RDI) Fund, the BioE3 policy, and regulatory support for advanced genetic technologies, the country is positioning itself for rapid innovation-led growth. A growing talent pool, returning global expertise, expanding pharma GCCs, and capital-efficient manufacturing further strengthen India's advantage. Together, these factors create a strong foundation for globally competitive, sustainable science-driven enterprises.

India’s biotech industry is currently undergoing a long awaited shift from being the generics capital of the world to an innovation hub. More than $900 million have been invested into cutting edge IP led startups in therapeutics, diagnostics and industrial biotech over the last seven years, according to Ankur Capital’s Deep Science Tech Report 2025. The journey of deep science biotechnology driven startups in India began in the early 2010’s with companies such as String Bio, Bugworks and Zumutor Biologics pushing the boundaries to develop novel drugs and agri inputs using synthetic biology and precision fermentation. While their journey has been long and hard and yet to see large outcomes, they laid the foundations for cutting edge innovations in biotechnology emerging from India for the world.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Korea opens door to B cell-based personalised cancer vaccines

Researchers from the Department of Bio and Brain Engineering at Korea Advanced Institute of Science and Technology (KAIST), in collaboration with Neogen Logic Co., have developed a new artificial intelligence (AI) model to predict neoantigens, a core element of personalised cancer vaccine development, and clarified the importance of B cells in cancer immunotherapy.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Chad May steps in as Chief Scientific Officer at Orum Therapeutics

Orum Therapeutics, a biotechnology company based in the US and South Korea, has announced the appointment of Dr Chad May as Chief Scientific Officer (CSO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

PAHO reviews measles elimination status in United States and Mexico

The Pan American Health Organization (PAHO) Regional Monitoring and Re-Verification Commission for Measles, Rubella, and Congenital Rubella Syndrome (RVC) has invited the United States and Mexico to meet virtually on April 13, 2026, to review their measles elimination status.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

US FDA approves first treatment for children with Menkes Disease

The US Food and Drug Administration (FDA) has approved the Zycubo (copper histidinate) injection, to Sentynl Therapeutics, as the first treatment for Menkes disease in paediatric patients.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

SINGAPORE SHOWS WHAT TARIFFS CAN'T

While U.S. President Donald Trump was publicly defending his threat of higher import tariffs on medicines, Singapore was quietly experiencing an unexpected upside: a surge in pharmaceutical production.

time to read

2 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Hong Kong designs mucus-inspired hydrogel to boost gastrointestinal wound healing

The Hong Kong Polytechnic University (PolyU) has developed an acid-resistant “ultra-stable mucus-inspired hydrogel” (UMIH), marking a breakthrough in the field of gastrointestinal medicine.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Africa lifts Mpox as Public Health Emergency of Continental Security

Africa has officially lifted Mpox as a Public Health Emergency of Continental Security following recommendations from the Africa CDC Emergency Consultative Group.

time to read

1 min

BioSpectrum Asia Feb 2026

Listen

Translate

Share

-
+

Change font size